A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder - P24-05
Latest Information Update: 19 Jan 2026
At a glance
- Drugs BP 14979 (Primary)
- Indications Obsessive-compulsive disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Bioprojet
Most Recent Events
- 19 Jan 2026 New trial record